Terumo Blood and Cell Technologies

Did you know the quality of T cells is critical for a successful cell therapy? It's more than just the count. Watch Mindy Miller discuss the importance of collecting T cells at their peak fitness and preserving their phenotype for optimal cell therapy outcomes. Learn more in our #whitepaper on cellular acquisitions for optimal starting material: https://bit.ly/3QA8Qo2 #celltherapy #cellcollection #biomanufacturing #pharma #lifesciences #Tcells #immunology #InnovationandQuality

“At a moment when medication therapy for sickle cell disease (SCD) leaves too many behind and widespread access to curative gene therapies still lies in the distant future, automated red blood cell exchange is experiencing renewed interest. To improve patients’ lives, a broad commitment is needed to expand access to transfusion therapies.” Read the full article in MedCityNews by Koenraad Dierick, MBA, our VP of Patient Access. Koenraad leads a global team of experts in government affairs, medical affairs, and market access, all focused on removing barriers that prevent patients from receiving the care they need: https://lnkd.in/gHHA_54t Join the conversation on how we can improve access to care for SCD patients by following us on LinkedIn, Facebook, and X. LinkedIn: https://bit.ly/4imsQX4 Facebook: https://bit.ly/41CAzum X: https://bit.ly/3QKblUS #SickleCellAwareness #HealthcareAdvancement #PatientAccess #TransfusionTherapy #MedicalAdvocacy #TerumoBCT

Recently, our President & CEO, Antoinette Gawin, and Global Commerical SVP, Cindy Ng, visited Mexico for a day filled with idea-sharing, leadership, and connection with our Latin America team and strategic partners. The day began with a meeting alongside our Functional and Commercial Leadership Team, where Antoinette shared her vision, life experiences, and insights on achieving a balance between personal and professional life. During the Town Hall, Antoinette reinforced Terumo BCT’s commitment to innovation and making a positive impact on healthcare by presenting our global strategy and values. In the afternoon, Antoinette opened a meeting with our distributors, Manlio Fabio Lopez, Country Manager in Mexico, expressed gratitude for their collaboration, and Cindy closed with a toast in recognition of their work. The day then ended with a tour of the Terumo Medical Training Center, reaffirming our commitment to excellence. We are grateful to everyone who made this enriching day possible. As we reflect on leadership and progress, let’s continue driving the future of healthcare—together. #TerumoBCT #Leadership #Innovation #TownHallMexico #IWD2025 #WomenInLeadership #InspiringChange

Two weeks ago, Terumo BCT reached a significant milestone. We hosted our first LinkedIn Live event, attracting viewers from across the globe and various professions, including healthcare administrators, marketing professionals, scientists, advocates, policy makers, and CEOs. Participants joined us from Tanzania, Kenya, India, Egypt, the UK, the US, France, Brazil, Spain, Scotland, and more—spanning five continents. Our speakers shared powerful and humbling insights about living with Sickle Cell Disease (SCD) and the current state of SCD treatments in the healthcare industry. We are deeply grateful to Kevin Wake, M.S., CHW, for sharing his journey with SCD and his determination to receive regular treatments within specific timeframes. His story reminded us and our attendees of the daily battles many face, often greater than our own. Witnessing individuals like Kevin pursue a life filled with joy despite obstacles inspires us at Terumo BCT to continue advocating for patient care and accessible treatments for blood disorders. We extend our heartfelt thanks to Mason Barrett from National Organization for Rare Disorders (NORD) for highlighting resources to support rare diseases and for his unwavering commitment to advancing this mission despite current challenges. We also thank Jackie Kunzler for contributing to this important conversation and for leading discussions on critical topics related to healthcare advancement and access. Lastly, we are grateful to everyone who tuned in to this conversation. Your efforts in spreading awareness within your networks help us make a positive impact on many lives. Thank you. If you missed the Rare Disease Day LinkedIn Live, you can watch it here: https://bit.ly/4kq1YXM #SickleCellAwareness #SCDWarrior #HealthcareAccess #PatientAdvocacy #TerumoBCT #TerumoBloodandCellTechnologies

Building an inclusive culture can’t be done by creating policies or posting statements online—it comes from valuing and appreciating our colleagues’ lived experiences. While leadership plays a role in setting priorities, real inclusion happens by living your Core Values. At Terumo Blood and Cell Technologies, these values shape the conversations we choose to have, the respect we show to each other, and the care we demonstrate to our colleagues and the patients we serve. The power of inclusion lies in individual actions. It’s how we listen, how we seek and appreciate different perspectives, and how we ensure every person feels valued and heard. Creating a culture where people can bring their whole, authentic selves to work isn’t just an initiative on a website—it’s a collective responsibility we bring to team meetings, company events and hallway conversations. Inclusion can't be mandated from the top-down; it has to be built from the ground up. Our entire business thrives when we make space for each other, when we challenge biases (our own and those around us) and when we choose curiosity over assumption. I'm proud to work for Terumo Blood and Cell Technologies, where we continue to prioritize this through our leaders and champions, enabled by a Center of Excellence within our HR organization led by Jessie Rowe and her team. So as we approach?International Women's Day?this weekend, let’s continue to do the work—not just in words, but in actions. Because inclusion isn’t about a program. It’s about our habits and actions everyday.? #IWD #AccelerateAction #TerumoProud

Terumo DE&I Week starts today, and we kick it off with a message from Chief Executive Officer Hikaru Samejima, who reflects on his personal practice of DE&I and its importance in driving growth and corporate value. Our CEO believes that the active participation of diverse talents is the foundation of the company’s success. In his practice of #DEI, he is committed to inclusive leadership, ensuring that diverse associates can bring their authentic selves and voices to the discussion.? DE&I Week is an annual event across the Terumo Group, bringing us together to celebrate and promote #diversity, #equity, and #inclusion throughout our organization. It’s an opportunity to deepen our understanding, foster an inclusive culture, and strengthen our unity. Let’s continue to build a workplace where everyone can thrive.

Ever faced the challenge of platelet clumping during cell collection? It’s a common hurdle for professionals in the biopharma and biotech industries, but there’s a way to overcome it. Watch Sara Lewandowski explain more about clumping and how Terumo Blood and Cell Technologies can help optimize collection procedures to achieve desired purity levels – and other desired manufacturing or #apheresiscollection characteristics. Learn more about overcoming the challenges of platelet clumping and optimizing the cell collection process in our #whitepaper: https://bit.ly/3QA8Qo2 #CellTherapy #Biopharma #Biotech #CellManufacturing #Apheresis #DataAnalytics #InnovationandQuality

?? Sickle cell is a genetic blood disorder that causes misshapen red blood cells to get stuck in blood vessels—leading to severe pain episodes, significant organ damage and an increased risk of early death. Luckily, a range of disease-modifying treatments for sickle cell exist, including blood-based therapies such as automated red blood cell exchange. Recently, Terumo Blood and Cell Technologies and the National Alliance of Sickle Cell Centers NASCC have partnered to make these treatments more accessible. The partnership focuses on our collective belief that blood is an essential therapy. ?? Learn more about our key initiatives here: https://bit.ly/4hWgHbA #SickleCellAwareness #BloodTherapy #SickleCell #PatientAccess #BloodisEssentialTherapy #aRBCX #SCD

?? Just back from an incredible #CARTCRsummit Europe 2025 in London! ?? From cutting-edge insights on T-cell engineering and gene editing to streamlined manufacturing solutions, the conference showcased the future of CAR-T and TCR therapies. ?? Highlights included live demos of Quantum Flex Cell Expansion and Finia Fill & Finish, along with an inspiring presentation by Mindy Miller on tailoring cell therapy processes to produce high-quality CAR-T cells, boost Tscm frequency, and optimize growth conditions with automated sensing – driving cell therapy innovation. ?? We’re excited about the opportunities ahead and how collaboration continues to drive the cell therapy market forward. Let’s connect to explore how we can advance cell therapy solutions together: https://lnkd.in/gYnCBmTP #ATMP #CellTherapy #GeneTherapy #HealthcareInnovation #FutureOfMedicine

Have you ever wondered about the true impact of cell contamination? It’s not just about the risk – it’s about understanding the full impact. Rachel Garcia and fellow authors Mindy Miller and Sara Lewandowski cover the importance of understanding the specific impact of different cell contaminants. How do we know these impacts? Through our data and expertise. Our data analytics go beyond simply identifying risks – we show you how contaminants can affect the entire manufacturing process. Explore more of this insight in our #whitepaper on cellular acquisitions and achieving optimal starting material: https://bit.ly/3QA8Qo2 #CellTherapy #Biopharma #Biotech #CellManufacturing #Apheresis #DataAnalytics